Organon & Co.
Close on Oct 19, 2026
- Market cap
- $3.72B
- P/E (TTM)
- 17.6
- Dividend yield
- 2.47%
Earnings
Quarterly results announced on Form 8-K, Item 2.02
| Quarter | Reported | Time | Revenue | EPS (GAAP) | EPS (adjusted) |
|---|---|---|---|---|---|
| Q1 FY2026 Ended Mar 31, 2026 | Apr 30, 2026 | Before market open | $1.46B | $0.55 | $0.71 |
| Q4 FY2025 Ended Dec 31, 2025 | Feb 12, 2026 | Before market open | $1.51B | $-0.79 | $0.63 |
| Q3 FY2025 Ended Sep 30, 2025 | Nov 10, 2025 | Before market open | $1.60B | $0.61 | $1.01 |
| Q2 FY2025 Ended Jun 30, 2025 | Aug 5, 2025 | Before market open | $1.59B | $0.56 | $1.00 |
| Q1 FY2025 Ended Mar 31, 2025 | May 1, 2025 | Before market open | $1.51B | $0.33 | $1.02 |
| Q4 FY2024 Ended Dec 31, 2024 | Feb 13, 2025 | Before market open | $1.59B | $0.42 | $0.90 |
| Q3 FY2024 Ended Sep 30, 2024 | Oct 31, 2024 | Before market open | $1.58B | $1.38 | $0.87 |
| Q2 FY2024 Ended Jun 30, 2024 | Aug 6, 2024 | Before market open | $1.61B | $0.75 | $1.12 |
| Q1 FY2024 Ended Mar 31, 2024 | May 2, 2024 | Before market open | – | – | – |
| Q4 FY2023 Ended Dec 31, 2023 | Feb 15, 2024 | Before market open | – | – | – |
| Q3 FY2023 Ended Sep 30, 2023 | Nov 2, 2023 | Before market open | – | – | – |
| Q2 FY2023 Ended Jun 30, 2023 | Aug 8, 2023 | Before market open | – | – | – |
Company guidance
Outlook given with results on Feb 12, 2026, compared with the previous outlook
| Measure | Period | Guidance | vs. prior |
|---|---|---|---|
| Adjusted EBITDAnon-GAAP | full year 2026 | $1.90B | New |
| Fully diluted weighted average shares outstandingnon-GAAP | Full Year 2026 Guidance | 265 | New |
| Effective non-GAAP tax ratenon-GAAP | Full Year 2026 Guidance | 27.5% to 29.5% | New |
| Ex-FX revenue growthnon-GAAP | Full Year 2026 Guidance | -1.5% growth | New |
| Interestnon-GAAP | Full Year 2026 Guidance | $500.00M | New |
| Depreciationnon-GAAP | Full Year 2026 Guidance | $140.00M | Lowered |
| FX translation impactnon-GAAP | Full Year 2026 Guidance | $75.00M | Lowered |
| revenue | full year 2026 | $6.20B | New |
Figures and the sentence they come from are taken from the company's earnings release. Hover a measure to read the source sentence.
Press releases
Announcements Organon filed with the SEC
This exhibit provides certain supplemental non-GAAP
Regulation FD disclosure · EX-99.1 to Form 8-K
Organon Reports Results for the First Quarter
Results of operations · EX-99.1 to Form 8-K
Sun Pharma signs Definitive Agreement to Acquire Organon
Material agreement · Executive or director change · Regulation FD disclosure · EX-99.1 to Form 8-K
Organon Reports Results for the Fourth Quarter
Results of operations · Regulation FD disclosure · EX-99.1 to Form 8-K
Fourth Quarter and Full Year 2025 Earnings Organon
Results of operations · Regulation FD disclosure · EX-99.2 to Form 8-K
Organon Reports Results for the Third Quarter
Results of operations · Regulation FD disclosure · EX-99.1 to Form 8-K
Third Quarter 2025 Earnings Organon
Results of operations · Regulation FD disclosure · EX-99.2 to Form 8-K
Executive Joseph Morrissey as Interim CEO and Board Chair Carrie Cox as Executive Chair; Announces Results of Audit Committee Investigation
Executive or director change · Other events · EX-99.1 to Form 8-K
Organon Reports Results for the Second Quarter
Results of operations · Regulation FD disclosure · EX-99.1 to Form 8-K
Second Quarter 2025 Earnings Organon
Results of operations · Regulation FD disclosure · EX-99.2 to Form 8-K
US Food and Drug Administration (FDA) Grants Interchangeability
Other events · EX-99.1 to Form 8-K
Organon Reports Results for the First Quarter
Results of operations · Regulation FD disclosure · Other events · EX-99.1 to Form 8-K
First Quarter 2025 Earnings Organon
Results of operations · Regulation FD disclosure · Other events · EX-99.2 to Form 8-K
Organon Appoints Ramona A. Sequeira to the Company’s
Executive or director change · Regulation FD disclosure · EX-99.1 to Form 8-K
Organon Reports Results for the Fourth Quarter
Results of operations · Regulation FD disclosure · EX-99.1 to Form 8-K
Fourth Quarter and Full Year 2024 Earnings Organon
Results of operations · Regulation FD disclosure · EX-99.2 to Form 8-K
Review of VTAMA ® (tapinarof) Cream, 1% for the Treatment of Atopic Dermatitis in Adults and Children 2 Years of Age and
Regulation FD disclosure · EX-99.1 to Form 8-K
Organon Reports Results for the Third Quarter
Results of operations · Regulation FD disclosure · EX-99.1 to Form 8-K
Third Quarter 2024 Earnings Organon
Results of operations · Regulation FD disclosure · EX-99.2 to Form 8-K
Organon Reports Results for the Second Quarter
Results of operations · Regulation FD disclosure · EX-99.1 to Form 8-K
Second Quarter 2024 Earnings Organon
Results of operations · Regulation FD disclosure · EX-99.2 to Form 8-K
Organon Reports Results for the First Quarter
Results of operations · Regulation FD disclosure · EX-99.1 to Form 8-K
First Quarter 2024 Earnings Organon
Results of operations · Regulation FD disclosure · EX-99.2 to Form 8-K
Results for the Fourth Quarter and Full Year Ended December 31, 2023
Results of operations · Regulation FD disclosure · EX-99.1 to Form 8-K
[Organon] Confidential Fourth Quarter and Full Year 2023 Earnings Organon
Results of operations · Regulation FD disclosure · EX-99.2 to Form 8-K
Organon Reports Results for the Third Quarter
Results of operations · Regulation FD disclosure · EX-99.1 to Form 8-K
[Organon] Confidential Third Quarter 2023 Earnings Organon
Results of operations · Regulation FD disclosure · EX-99.2 to Form 8-K
Organon Reports Results for the Second Quarter
Results of operations · Regulation FD disclosure · EX-99.1 to Form 8-K
Second Quarter 2023 Earnings Organon
Results of operations · Regulation FD disclosure · EX-99.2 to Form 8-K
Organon Reports Results for the First Quarter
Results of operations · Regulation FD disclosure · EX-99.1 to Form 8-K
First Quarter 2023 Earnings Organon
Results of operations · Regulation FD disclosure · EX-99.2 to Form 8-K
Organon Reports Results for the Fourth Quarter
Results of operations · Regulation FD disclosure · EX-99.1 to Form 8-K
Fourth Quarter and Full Year 2022 Earnings Organon
Results of operations · Regulation FD disclosure · EX-99.2 to Form 8-K
rep orts results for the third quarter ended September 30, 2022
Results of operations · Regulation FD disclosure · EX-99.1 to Form 8-K
[Organon] Confidential Q3 2022 Earnings Organon
Results of operations · Regulation FD disclosure · EX-99.2 to Form 8-K
Organon reports results for the second quarter
Results of operations · Regulation FD disclosure · EX-99.1 to Form 8-K
Established Brands sizeable and stable base of revenue $ mil 18
Results of operations · Regulation FD disclosure · EX-99.2 to Form 8-K
Ladies and gentlemen, thank you for standing by.
Regulation FD disclosure · EX-99.1 to Form 8-K
Organon reports results for the first quarter
Results of operations · Regulation FD disclosure · EX-99.1 to Form 8-K
Established Brands sizeable and stable base of revenue $ mil 5
Results of operations · Regulation FD disclosure · EX-99.2 to Form 8-K